VRCA
Verrica Pharmaceuticals Inc
$
3.460
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.510
Open
3.510
VWAP
3.45
Vol
72.08K
Mkt Cap
32.68M
Low
3.360
Amount
248.35K
EV/EBITDA(TTM)
--
Total Shares
42.42M
EV
55.88M
EV/OCF(TTM)
--
P/S(TTM)
1.85
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
10.10M
+2836.05%
--
--
8.34M
-568.42%
--
--
4.27M
-17.58%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Verrica Pharmaceuticals Inc. (VRCA) for FY2025, with the revenue forecasts being adjusted by 49.19% over the past three months. During the same period, the stock price has changed by -45.51%.
Revenue Estimates for FY2025
Revise Upward
+49.19%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-73.92%
In Past 3 Month
Stock Price
Go Down
-45.51%
In Past 3 Month
2 Analyst Rating
Wall Street analysts forecast VRCA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRCA is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 3.460
Low
20.00
Averages
20.00
High
20.00
Current: 3.460
Low
20.00
Averages
20.00
High
20.00
Lucid Capital
NULL -> Buy
initiated
$19
2025-11-05
New
Reason
Lucid Capital
Price Target
$19
2025-11-05
New
initiated
NULL -> Buy
Reason
Lucid Capital initiated coverage of Verrica Pharmaceuticals with a Buy rating and $19 price target. The firm views Verrica as a "de-risked" dermatology platform transitioning to a scalable growth model with expanding global leverage and strong capital efficiency. The company's Ycanth holds a first-mover advantage as the only in-office FDA-approved therapy for molluscum contagiosum, a large, underpenetrated pediatric market with broad payer coverage, the analyst tells investors in a research note.
Needham
Serge Belanger
Hold
Reiterates
n/a
2025-04-09
Reason
Needham
Serge Belanger
Price Target
n/a
2025-04-09
Reiterates
Hold
Reason
HC Wainwright & Co.
Oren Livnat
Hold
Reiterates
n/a
2025-04-08
Reason
HC Wainwright & Co.
Oren Livnat
Price Target
n/a
2025-04-08
Reiterates
Hold
Reason
Needham
Serge Belanger
Hold
Reiterates
n/a
2025-03-12
Reason
Needham
Serge Belanger
Price Target
n/a
2025-03-12
Reiterates
Hold
Reason
Needham
Serge Belanger
Hold
Reiterates
n/a
2024-12-20
Reason
Needham
Serge Belanger
Price Target
n/a
2024-12-20
Reiterates
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Verrica Pharmaceuticals Inc (VRCA.O) is -2.22, compared to its 5-year average forward P/E of -4.32. For a more detailed relative valuation and DCF analysis to assess Verrica Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.32
Current PE
-2.22
Overvalued PE
-1.88
Undervalued PE
-6.76
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.99
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.28
Undervalued EV/EBITDA
-5.70
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
34.14
Current PS
3.45
Overvalued PS
73.49
Undervalued PS
-5.21
Financials
Annual
Quarterly
FY2025Q2
YoY :
+145.35%
12.70M
Total Revenue
FY2025Q2
YoY :
-109.93%
1.51M
Operating Profit
FY2025Q2
YoY :
-101.19%
204.00K
Net Income after Tax
FY2025Q2
YoY :
-100.54%
0.02
EPS - Diluted
FY2025Q2
YoY :
-38.64%
-10.04M
Free Cash Flow
FY2025Q2
YoY :
+7.35%
96.11
Gross Profit Margin - %
FY2025Q2
-322.08
FCF Margin - %
FY2025Q2
YoY :
-100.48%
1.61
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
2.8K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
3.9M
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
2.8K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
VRCA News & Events
Events Timeline
2025-10-20 (ET)
2025-10-20
16:42:37
Verrica Pharmaceuticals Receives CHMP Endorsement for Ycanth MAA Submission
2025-09-19 (ET)
2025-09-19
08:02:40
Verrica Pharmaceuticals' development partner gets approval for YCANTH
2025-07-09 (ET)
2025-07-09
07:11:50
Verrica reports 13,434 YCANTH dispensed applicator units in Q2
Sign Up For More Events
Sign Up For More Events
News
9.0
10-20NewsfilterVerrica Pharmaceuticals Gains Favorable Response from EMA, Paving the Way for YCANTH® Approval in the EU
9.0
09-19NewsfilterVerrica Pharmaceuticals Reports Approval of YCANTH® (TO-208) in Japan for Molluscum Contagiosum Treatment by Development Partner Torii Pharmaceutical
9.5
08-13NewsfilterVerrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript
Sign Up For More News
People Also Watch
NIXX
Nixxy Inc
1.420
USD
-5.33%
APT
Alpha Pro Tech Ltd
4.685
USD
+0.86%
NVA
Nova Minerals Ltd
8.870
USD
+29.68%
SRFM
Surf Air Mobility Inc
3.320
USD
+0.30%
WAVE
Eco Wave Power Global AB (publ)
7.420
USD
+0.13%
IPWR
Ideal Power Inc
5.040
USD
-0.20%
WAI
Top KingWin Ltd
3.100
USD
-6.34%
RVPH
Reviva Pharmaceuticals Holdings Inc
0.504
USD
+0.80%
FAQ
What is Verrica Pharmaceuticals Inc (VRCA) stock price today?
The current price of VRCA is 3.46 USD — it has decreased -3.35 % in the last trading day.
What is Verrica Pharmaceuticals Inc (VRCA)'s business?
What is the price predicton of VRCA Stock?
What is Verrica Pharmaceuticals Inc (VRCA)'s revenue for the last quarter?
What is Verrica Pharmaceuticals Inc (VRCA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Verrica Pharmaceuticals Inc (VRCA)'s fundamentals?
How many employees does Verrica Pharmaceuticals Inc (VRCA). have?